Compare · LSB vs NVO
LSB vs NVO
Side-by-side comparison of LakeShore Biopharma Co. Ltd (LSB) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LSB and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO carries a market cap of $187.53B.
- NVO has hit the wire 11 times in the past 4 weeks while LSB has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 0 for LSB).
- Company
- LakeShore Biopharma Co. Ltd
- Novo Nordisk A/S
- Price
- $0.63-24.33%
- $42.01-2.10%
- Market cap
- -
- $187.53B
- 1M return
- -20.59%
- -
- 1Y return
- -41.92%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 0
- 11
- Recent ratings
- 0
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest LSB
- SEC Form 25-NSE filed by LakeShore Biopharma Co. Ltd
- SEC Form 6-K filed by LakeShore Biopharma Co. Ltd
- SEC Form 6-K filed by LakeShore Biopharma Co. Ltd
- LakeShore Biopharma Announces Transition to OTC Market Following Nasdaq Delisting
- SEC Form 6-K filed by LakeShore Biopharma Co. Ltd
- LakeShore Biopharma Announces Receipt of Delisting Determination Letter from Nasdaq
- SEC Form 6-K filed by LakeShore Biopharma Co. Ltd
- LakeShore Biopharma Announces Appointment of Independent Financial Advisor and Legal Counsel to the Special Committee
- SEC Form 6-K filed by LakeShore Biopharma Co. Ltd
- LakeShore Biopharma Announces Receipt of a Revised Preliminary Non-Binding Proposal to Acquire the Company and Formation of Special Committee
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
- Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates